Skip to main navigation
Intercept Pharmaceuticals homepage
  • News
  • Contact Us
Intercept Pharmaceuticals Logo
Menu
Close✕
  • Our Focus
    • Rare and Serious Liver Diseases
      • Meet Ally
      • Racial Disparities in PBC
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
      • Expanded Access
    • Clinical Trials
    • Medical Information Request Form
  • Our Medicine
  • About Us
    • Leadership
    • News
    • Company Statements
  • Careers
    • Job Postings
    • Culture
    • US Benefits
  • Media
  • Contact Us
Home > Our Research > FXR
  • Our Research
    • FXR
    • Pipeline
      • Expanded Access
    • Clinical Trials
    • Medical Information Request Form
    • Medical Information Request Form

Farnesoid X Receptor (FXR)

The Core of Intercept's Research

FXR, a nuclear receptor expressed in the liver and intestine, is a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways.


Understanding FXR

  • FXR is a nuclear receptor found in the liver, intestine, kidney, and adipose tissue

  • FXR regulates many biological processes, including:
    • Bile acid metabolism
    • Inflammation
    • Fibrosis
    • Glucose metabolism
    • Lipid metabolism

In addition to their role in digestion and absorption, bile acids have been shown to bind and activate dedicated receptors like FXR.

Intercept's lead compound, obeticholic acid (OCA), is an analog of the bile acid chenodeoxycholic acid (CDCA).


FXR Resources

  1. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease (Xu et al, World Journal of Gastroenterology, 2014)
  2. Pleiotropic roles of bile acids in metabolism (de Aguiar Vallim et al, Cell Metabolism, 2013)
  3. Physiological and molecular biochemical mechanisms of bile formation (Reshetnyak, World Journal of Gastroenterology, 2013)
  4. Bile acid transporters and regulatory nuclear receptors in the liver and beyond (Halilbasic et al, Journal of Hepatology, 2012)
  5. Deciphering the nuclear bile acid receptor FXR paradigm (Modica et al, Nuclear Receptor Signaling, Nov 2010)
  6. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease (Claudel et al, Biochimica et Biophysica Acta, 2010)
  7. Role of bile acids and bile acid receptors in metabolic regulation (Lefebvre et al, Physiological Review, 2009)
  8. Bile acids as regulatory molecules (Hylemon et al, Journal of Lipid Research, 2009)
  9. The role of FXR in disorders of bile acid homeostasis (Eloranta et al, Physiology, 2008)
  10. 6-α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity (Pellicciari et al, Journal of Medicinal Chemistry, 2002)
  11. Identification of a nuclear receptor that is activated by farnesol metabolites (Forman et al, Cell, 1995)
  12. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors (Seol et al, Molecular Endocrinology, 1995)
  • Our Focus
    • Rare and Serious Liver Diseases
      • Meet Ally
      • Racial Disparities in PBC
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
      • Expanded Access
    • Clinical Trials
    • Medical Information Request Form
  • Our Medicine
  • About Us
    • Leadership >
    • News >
  • Careers
    • Job Postings
    • Culture
    • US Benefits
Intercept Pharmaceuticals Logo
  • Website Privacy Policy
  • Consumer Health Data Privacy Policy
  • EU-US Data Privacy Framework (DPF) Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
  • Transparency Disclosures
305 Madison Avenue |Morristown, NJ 07960|T: (844) 782–4278
© 2024 Intercept Pharmaceuticals, Inc.
US-NP-PB-1861
US-NP-PB-1861

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.

Continue

YOU ARE NOW leaving interceptpharma.com


You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.

Continue

YOU ARE NOW leaving interceptpharma.com


The link you have selected will take you outside of Intercept Pharmaceuticals’ corporate website.
The site you will be entering is intended for U.S. audiences only.

Continue


If you are a healthcare provider looking for product information, visit ocalivahcp.com.

YOU ARE NOW leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.

Continue

United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)

Close

Exploring Racial Differences and Disparities in PBC Care